VRTX · Vertex Pharmaceuticals Incorpor
$477.36
+2.65% last session
End-of-day data · updated 2026-07-28
Market cap
$122B
Enterprise value
$116B
Trailing P/E
28.4
Forward P/E
22.5
Dividend yield
—
Beta
0.29
Avg volume
2M
Employees
6K
2D change
—
5D change
1.25%
10D change
-1.37%
30D change
-2.51%
60D change
7.03%
MTD change
-3.82%
YTD change
5.66%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — VRTX
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-07-13
Latest call per bank · past 12 months
UBS
Buy$585
+22.5% vs priceRBC Capital
Outperform$570
+19.4% vs priceBarclays
Overweight$615
+28.8% vs priceMorgan Stanley
Overweight$616
+29.0% vs priceBank of America
Buy$598
+25.3% vs priceCitigroup
Buy$585
+22.5% vs priceJefferies
Buy$580
+21.5% vs priceWells Fargo
Overweight$515
+7.9% vs priceJP Morgan
Overweight$530
+11.0% vs priceRecent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-07-13 | UBS | Maintains | Buy | $545 → $585 |
| 2026-07-13 | Truist Securities | Maintains | Buy | $542 → $560 |
| 2026-07-07 | RBC Capital | Maintains | Outperform | $543 → $570 |
| 2026-07-07 | Baird | Maintains | Underperform | $330 → $350 |
| 2026-05-06 | Barclays | Maintains | Overweight | $607 → $615 |
| 2026-05-05 | Canaccord Genuity | Maintains | Hold | $437 → $436 |
| 2026-05-05 | Morgan Stanley | Maintains | Overweight | $612 → $616 |
| 2026-05-05 | Bernstein | Maintains | Outperform | $577 → $572 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
Signal Summary as of 2026-07-28
- RSI (14): RSI is 57 — neutral momentum, neither overbought nor oversold.
- Price vs 50-day MA: Trading 5.7% above the 50-day MA ($465.10).
- Price vs 200-day MA: Trading 8.9% above the 200-day MA ($451.60).
- MA cross: The 50-day MA sits above the 200-day MA (golden-cross regime) — the longer-term trend points up.
- MACD (12,26,9): MACD histogram is negative (-2.60) — short-term momentum is fading.
- 52-week range: Price sits between the 52-week low ($366.54) and high ($529.59).
VRTX Price Chart
Loading chart for VRTX…
Fundamentals
About Vertex Pharmaceuticals Incorpor
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
More in Biotechnology
REGN
Regeneron Pharmaceuticals, Inc.
$70B -13.3% YTD
ARGX
argenx SE
$56B 5.7% YTD
RVMD
Revolution Medicines, Inc.
$40B 136.1% YTD
ALNY
Alnylam Pharmaceuticals, Inc.
$37B -30.0% YTD
ONC
BeOne Medicines Ltd.
$34B 7.3% YTD
RPRX
Royalty Pharma plc
$34B 53.5% YTD
ROIV
Roivant Sciences Ltd.
$25B 60.0% YTD
INCY
Incyte Corporation
$24B 20.3% YTD
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.